Alimera Sciences, Inc. (ALIM) Research

Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.

Market snapshot

Symbol
ALIM
Price
$5.54
Day change
-0.18%
Market cap
$301.3M
P/E ratio
-7.03x
52-week range
2.606-5.65
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Analyst price target
$5.75

Peer companies

  • Adamis Pharmaceuticals Corporation (ADMP)
  • Athenex, Inc. (ATNX)
  • China Pharma Holdings, Inc. (CPHI)
  • Cyclo Therapeutics, Inc. (CYTH)
  • Journey Medical Corporation (DERM)
  • Halo Collective Inc. (HCANF)
  • Lifecore Biomedical, Inc. (LFCR)
  • Lucy Scientific Discovery Inc. (LSDI)

Recent insider activity

  • Maltz Elliot — D-Return (75000 shares) on 2024-09-16
  • Maltz Elliot — D-Return (75000 shares) on 2024-09-16
  • Maltz Elliot — D-Return (75000 shares) on 2024-09-16
  • Kaseta Michael — D-Return (1825 shares) on 2024-09-16
  • Kaseta Michael — D-Return (50000 shares) on 2024-09-16

Open Alimera Sciences, Inc. (ALIM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.